Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Leading cancer centers launch Juno Therapeutics; company gets $120mm through Series A; later adds more

Executive Summary

The Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute joined forces to launch Juno Therapeutics Inc., a company tasked with developing T cell-based cancer immunotherapies. Arch Venture Partners and the Alaska Permanent Fund (managed by Crestline Investors) are initial investors in the start-up’s concurrent $120mm Series A round.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies